269 related articles for article (PubMed ID: 26862738)
1. Identification of drugs that restore primary cilium expression in cancer cells.
Khan NA; Willemarck N; Talebi A; Marchand A; Binda MM; Dehairs J; Rueda-Rincon N; Daniels VW; Bagadi M; Thimiri Govinda Raj DB; Vanderhoydonc F; Munck S; Chaltin P; Swinnen JV
Oncotarget; 2016 Mar; 7(9):9975-92. PubMed ID: 26862738
[TBL] [Abstract][Full Text] [Related]
2. HDAC2 promotes loss of primary cilia in pancreatic ductal adenocarcinoma.
Kobayashi T; Nakazono K; Tokuda M; Mashima Y; Dynlacht BD; Itoh H
EMBO Rep; 2017 Feb; 18(2):334-343. PubMed ID: 28028031
[TBL] [Abstract][Full Text] [Related]
3. Gefitinib inhibits the proliferation of pancreatic cancer cells via cell cycle arrest.
Zhou X; Zheng M; Chen F; Zhu Y; Yong W; Lin H; Sun Y; Han X
Anat Rec (Hoboken); 2009 Aug; 292(8):1122-7. PubMed ID: 19645012
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
5. Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells.
Azzariti A; Porcelli L; Gatti G; Nicolin A; Paradiso A
Biochem Pharmacol; 2008 Mar; 75(5):1035-44. PubMed ID: 18191814
[TBL] [Abstract][Full Text] [Related]
6. Role of primary cilium in pancreatic ductal adenocarcinoma (Review).
Sabanovic B; Giulietti M; Piva F
Int J Oncol; 2020 Nov; 57(5):1095-1102. PubMed ID: 33491761
[TBL] [Abstract][Full Text] [Related]
7. High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma.
Stenzinger A; Endris V; Klauschen F; Sinn B; Lorenz K; Warth A; Goeppert B; Ehemann V; Muckenhuber A; Kamphues C; Bahra M; Neuhaus P; Weichert W
BMC Cancer; 2013 Oct; 13():450. PubMed ID: 24088390
[TBL] [Abstract][Full Text] [Related]
8. Targeting Primary Ciliogenesis with Small-Molecule Inhibitors.
Guen VJ; Prigent C
Cell Chem Biol; 2020 Oct; 27(10):1224-1228. PubMed ID: 32795416
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological Regulation of Primary Cilium Formation Affects the Mechanosensitivity of Osteocytes.
Ding D; Yang X; Luan HQ; Wu XT; He C; Sun LW; Fan YB
Calcif Tissue Int; 2020 Dec; 107(6):625-635. PubMed ID: 32940720
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.
Pino MS; Shrader M; Baker CH; Cognetti F; Xiong HQ; Abbruzzese JL; McConkey DJ
Cancer Res; 2006 Apr; 66(7):3802-12. PubMed ID: 16585207
[TBL] [Abstract][Full Text] [Related]
11. Autophagy alteration prevents primary cilium disassembly in RPE1 cells.
Maharjan Y; Lee JN; Kwak S; Lim H; Dutta RK; Liu ZQ; So HS; Park R
Biochem Biophys Res Commun; 2018 Jun; 500(2):242-248. PubMed ID: 29649478
[TBL] [Abstract][Full Text] [Related]
12. Ciliogenesis and Hedgehog signalling are suppressed downstream of KRAS during acinar-ductal metaplasia in mouse.
Bangs FK; Miller P; O'Neill E
Dis Model Mech; 2020 Jul; 13(7):. PubMed ID: 32571902
[TBL] [Abstract][Full Text] [Related]
13. Biological Activity and Physicochemical Properties of Dipeptidyl Nitrile Derivatives Against Pancreatic Ductal Adenocarcinoma Cells.
Quilles JC; Bernardi MDL; Batista PHJ; Silva SCM; Rocha CMR; Montanari CA; Leitão A
Anticancer Agents Med Chem; 2019; 19(1):112-120. PubMed ID: 30370859
[TBL] [Abstract][Full Text] [Related]
14. Drug-induced ciliogenesis in pancreatic cancer cells is facilitated by the secreted ATP-purinergic receptor signaling pathway.
Khan NA; Garg AD; Agostinis P; Swinnen JV
Oncotarget; 2018 Jan; 9(3):3507-3518. PubMed ID: 29423062
[TBL] [Abstract][Full Text] [Related]
15. The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
Shen L; Li Z; Shen S; Niu X; Yu Y; Li Z; Liao M; Chen Z; Lu S
Lung Cancer; 2012 Dec; 78(3):193-200. PubMed ID: 22985911
[TBL] [Abstract][Full Text] [Related]
16. Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.
Aboukameel A; Muqbil I; Senapedis W; Baloglu E; Landesman Y; Shacham S; Kauffman M; Philip PA; Mohammad RM; Azmi AS
Mol Cancer Ther; 2017 Jan; 16(1):76-87. PubMed ID: 28062705
[TBL] [Abstract][Full Text] [Related]
17. Fibroblasts weaken the anti-tumor effect of gefitinib on co-cultured non-small cell lung cancer cells.
Yong X; Wang P; Jiang T; Yu W; Shang Y; Han Y; Zhang P; Li Q
Chin Med J (Engl); 2014; 127(11):2091-6. PubMed ID: 24890158
[TBL] [Abstract][Full Text] [Related]
18. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
[TBL] [Abstract][Full Text] [Related]
20. [Small molecule inhibitor SB203580 enhances the antitumor effect of gefitinib in PC-9 and A549 lung cancer cell lines].
Zhao YM; Su B; Yang XJ; Shi JY; Tang L; Zhang J; Li JY; Chen J
Zhonghua Zhong Liu Za Zhi; 2013 Feb; 35(2):103-8. PubMed ID: 23714663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
